Santen and SERI Launch SONIC 2.0 to Develop Novel Eye Disease Therapies
I'm PortAI, I can summarize articles.
Santen Pharmaceutical Co. Ltd. and the Singapore Eye Research Institute (SERI) have launched SONIC 2.0, a S$21 million initiative to develop novel therapies for major eye diseases. This collaboration aims to accelerate the development of first-in-class, disease-modifying treatments for conditions such as glaucoma, ocular surface diseases, presbyopia, and myopia. SONIC 2.0 builds on their partnership since 2014 and the achievements of SONIC 1.0, combining Santen’s pharmaceutical expertise with SERI’s clinical research capabilities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments